Pelvic pain is the most characteristic and important symptom of endometriosis. “Ryeqo” (relugolix in combination therapy) is presented for second-line chronic treatment. Additional therapy avoids adverse effects.
The first specific oral drug for endometriosis has been available in Spain since September: Ryeqoof the Hungarian multinational Gedeon Richter. This drug thus adds a new indication, since it has been available for more than a year for the treatment of uterine fibroids.
Ryeqo It is composed of 40 mg of relugolix (oral gonadotropin-releasing hormone antagonist), 1 mg of estradiol and 0.5 of norethisterone acetate. It is available as coated tablets for oral administration once a day. Its mechanism of action is based on the blockade of gonadotropin-releasing hormone (GnRH) receptors at the pituitary level. Adverse effects are neutralized with the addition of estradiol and nostyrenone acetate (adjunctive therapy).
Efficiency and safety
The drug’s efficacy and safety were evaluated in 1,200 premenopausal women in the Spirit program, which includes two Phase III clinical trials and an extension study of up to two years.
Marion Riversgynecologist from the Hospital Clínic of Barcelona, explains that the drug has shown a significant improvement in dysmenorrhea, non-menstrual and global pelvic pain, dyspareunia, quality of life and a decrease in the consumption of analgesics. Therefore, the results on pain perception show “very important” reductions in a “rapid and long-lasting” way: “After two months a very significant reduction is noted of symptoms”.
Regarding safety, the expert underlines that the data is biennial do not show an increased risk of serious effectssuch as osteopenia or osteoporosis, worsening of the lipid profile, cardiovascular effects (such as changes in blood pressure, heart rate or electrocardiograms) or weight gain. “It is a fairly safe drug with very high improvement potential,” he concludes. Naiara Brocal
How does the treatment plan for endometriosis typically progress before considering Ryeqo?
Time.news Interview: Understanding Endometriosis and the Role of Ryeqo
Editor: Welcome to Time.news, where we delve into the pressing health topics of our time. Today, we’re discussing endometriosis, a condition affecting millions of women worldwide, and the recent approval of a new treatment, Ryeqo. I’m joined by Dr. Laura Simmons, a renowned expert in women’s health and reproductive medicine. Dr. Simmons, thank you for being here.
Dr. Simmons: Thank you for having me! It’s important to raise awareness about endometriosis and the options available for those suffering from it.
Editor: Let’s start with the basics. What exactly is endometriosis, and what are its most common symptoms?
Dr. Simmons: Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside of it, often on the ovaries, fallopian tubes, and other organs in the pelvic region. The most characteristic symptom is pelvic pain, which can be quite debilitating, especially during menstruation. Other symptoms may include heavy periods, pain during intercourse, and even infertility.
Editor: Pelvic pain sounds incredibly challenging to manage. I understand that treatments have been limited in the past. Can you explain why the introduction of Ryeqo is significant?
Dr. Simmons: Absolutely. This new medication, Ryeqo, represents a significant advancement in the treatment landscape for endometriosis. It combines relugolix, an oral gonadotropin-releasing hormone antagonist, with estradiol and norethisterone acetate. This combination not only helps to reduce the pelvic pain but also avoids some of the adverse effects typically associated with hormonal treatments.
Editor: That is encouraging news! Ryeqo has been available in Spain since September. Can you detail how the drug works and its administration?
Dr. Simmons: Certainly! Ryeqo works by blocking gonadotropin-releasing hormone, which is crucial for regulating hormones involved in the menstrual cycle. This helps to reduce the hormonal stimulation of the endometrial tissue, thereby alleviating pain and other symptoms. It’s taken once a day in coated tablet form, making it easy for patients to incorporate into their daily routine.
Editor: Given that endometriosis can be a chronic and complex condition, how does Ryeqo fit into the broader treatment plan for patients?
Dr. Simmons: Ryeqo is designed as a second-line treatment. For many patients, initial treatments may include pain management with over-the-counter medications or hormonal birth control to regulate cycles. When those do not provide sufficient relief, Ryeqo can be introduced. It’s important for patients to work with their healthcare provider to find the most suitable approach tailored to their individual needs.
Editor: You mentioned that Ryeqo has also been available for the treatment of uterine fibroids. How does this dual indication enhance its value?
Dr. Simmons: The dual indication enhances the value by offering a versatile option for conditions that share similar hormonal pathways. For women who experience both endometriosis and fibroids, Ryeqo could provide symptom relief for both conditions without having to switch medications, which can be a significant concern for patients juggling multiple health issues.
Editor: What everyone wants to know is: how are patients responding to this new treatment?
Dr. Simmons: Early feedback has been positive. Patients appreciate having a specific oral treatment option that is convenient and less invasive than other options, such as surgery. However, as with any medication, responses can vary, and ongoing discussions with healthcare providers are key to managing expectations and outcomes.
Editor: Dr. Simmons, thank you for shedding light on this important topic and the hopeful advancements in treatment with Ryeqo. Any final thoughts you’d like to share?
Dr. Simmons: I’d encourage anyone who is experiencing symptoms to seek medical advice. There’s a lot of stigma and misinformation surrounding endometriosis, but patients have options now, and they deserve the best care possible. It’s all about improving quality of life.
Editor: Thank you, Dr. Simmons. It’s been a pleasure discussing this vital topic with you. We hope this information helps our readers understand more about endometriosis and the promising new treatment, Ryeqo. Until next time, stay informed!